HIM
Hillsdale Investment Management Portfolio holdings
AUM
$2.71B
1-Year Return
43.79%
This Quarter Return
+25.47%
1 Year Return
+43.79%
3 Year Return
+197.89%
5 Year Return
+621.69%
10 Year Return
+2,572.94%
AUM
$1.05B
AUM Growth
+$33.2M
(+3.3%)
Cap. Flow
-$91.6M
Cap. Flow
% of AUM
-8.7%
Top 10 Holdings %
Top 10 Hldgs %
20.46%
Holding
697
New
131
Increased
106
Reduced
223
Closed
120
Top Buys
| 1 |
TFI International
TFII
|
+$28.8M |
| 2 |
NGD
New Gold Inc
NGD
|
+$12.7M |
| 3 |
Magna International
MGA
|
+$11.1M |
| 4 |
Ovintiv
OVV
|
+$9.58M |
| 5 |
Kinross Gold
KGC
|
+$8.96M |
Top Sells
| 1 |
Stantec
STN
|
+$18.8M |
| 2 |
Celestica
CLS
|
+$15.9M |
| 3 |
Equinox Gold
EQX
|
+$14.5M |
| 4 |
OSB
Norbord Inc.
OSB
|
+$12.4M |
| 5 |
B2Gold
BTG
|
+$12.1M |
Sector Composition
| 1 | Technology | 19.25% |
| 2 | Industrials | 18.28% |
| 3 | Financials | 16.7% |
| 4 | Materials | 12.02% |
| 5 | Consumer Discretionary | 8.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Apogee Enterprises
APOG
$927M
| $25K | ﹤0.01% |
800
| – | – |
|
477
Gildan
GIL
$8.31B
| $22K | ﹤0.01% |
800
+300
| +60% | +$8.25K |
|
478
Novartis
NVS
$249B
| $21K | ﹤0.01% |
220
+70
| +47% | +$6.68K |
|
479
AllianceBernstein
AB
$4.29B
| $20K | ﹤0.01% |
600
| – | – |
|
480
Buckle
BKE
$3.04B
| $20K | ﹤0.01% |
+680
| New | +$20K |
|
481
Chunghwa Telecom
CHT
$34.3B
| $20K | ﹤0.01% |
520
| – | – |
|
482
Colgate-Palmolive
CL
$68B
| $20K | ﹤0.01% |
230
+120
| +109% | +$10.4K |
|
483
Dollar General
DG
$23.9B
| $20K | ﹤0.01% |
95
-2,400
| -96% | -$505K |
|
484
Ethan Allen Interiors
ETD
$772M
| $18K | ﹤0.01% |
+900
| New | +$18K |
|
485
Oaktree Specialty Lending
OCSL
$1.23B
| $18K | ﹤0.01% |
+1,067
| New | +$18K |
|
486
Big 5 Sporting Goods
BGFV
$32.8M
| $17K | ﹤0.01% |
+1,700
| New | +$17K |
|
487
Alphabet (Google) Class C
GOOG
$2.83T
| $14K | ﹤0.01% |
160
| – | – |
|
|
EQC
488
DELISTED
Equity Commonwealth
EQC
| $14K | ﹤0.01% |
520
-100
| -16% | -$2.69K |
|
489
Expeditors International
EXPD
$16.5B
| $11K | ﹤0.01% |
120
+20
| +20% | +$1.83K |
|
490
Kimberly-Clark
KMB
$43.1B
| $11K | ﹤0.01% |
80
-2,945
| -97% | -$405K |
|
491
Monster Beverage
MNST
$61.5B
| $11K | ﹤0.01% |
240
-11,600
| -98% | -$532K |
|
|
ALXN
492
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $11K | ﹤0.01% |
70
-4,500
| -98% | -$707K |
|
|
AMED
493
DELISTED
Amedisys
AMED
| $10K | ﹤0.01% |
+35
| New | +$10K |
|
494
Fresenius Medical Care
FMS
$14.7B
| $10K | ﹤0.01% |
250
| – | – |
|
495
GSK
GSK
$80.6B
| $10K | ﹤0.01% |
224
+24
| +12% | +$1.07K |
|
496
Novo Nordisk
NVO
$241B
| $10K | ﹤0.01% |
280
-60
| -18% | -$2.14K |
|
497
T Rowe Price
TROW
$23.8B
| $10K | ﹤0.01% |
65
| – | – |
|
498
Universal Health Services
UHS
$11.8B
| $10K | ﹤0.01% |
+75
| New | +$10K |
|
499
Church & Dwight Co
CHD
$23B
| $9K | ﹤0.01% |
100
-10
| -9% | -$900 |
|
500
Charles River Laboratories
CRL
$7.97B
| $9K | ﹤0.01% |
+35
| New | +$9K |
|